drugset / Trial / NCT01971385

Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis

NCT01971385 ↗

Phase 1 Completed 54 enrolled Massachusetts General Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

Subjects with a history of recurrent herpes labialis will be sensitized with either 2% SADBE or placebo. Following this, subjects sensitized with 2% SADBE will received.2% sqauric acid or.5% squaric acid on their cold sore within 72 hours of a recurrence. Subjects sensitized with placebo solution will receive placebo solution on their cold sore within 72 hours of a recurrence. Subjects will be followed for up to 6 mos after application of study medication.

Timeline

Start
2013-10
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Squaric Acid Dibutyl Ester Small molecule 0.2 % —
Comparator Squaric Acid Dibutyl Ester Small molecule 0.5 % —

Indications